[go: up one dir, main page]

WO2000049019A3 - Novel epothilone derivatives, method for producing them and their pharmaceutical use - Google Patents

Novel epothilone derivatives, method for producing them and their pharmaceutical use Download PDF

Info

Publication number
WO2000049019A3
WO2000049019A3 PCT/EP2000/001331 EP0001331W WO0049019A3 WO 2000049019 A3 WO2000049019 A3 WO 2000049019A3 EP 0001331 W EP0001331 W EP 0001331W WO 0049019 A3 WO0049019 A3 WO 0049019A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
novel
epothilone derivatives
tumours
order
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2000/001331
Other languages
German (de)
French (fr)
Other versions
WO2000049019A2 (en
Inventor
Ulrich Klar
Wolfgang Schwede
Werner Skuballa
Bernd Buchmann
Michael Schirner
Andreas Menrad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Priority to AU38048/00A priority Critical patent/AU3804800A/en
Publication of WO2000049019A2 publication Critical patent/WO2000049019A2/en
Publication of WO2000049019A3 publication Critical patent/WO2000049019A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to novel epothilone derivatives of general formula (I), wherein the substituents Y, Z, R?1a, R1b, R2a, R2b¿, G'-G-E-E', R?5, R6, R7, R8, R14¿ and X have the meanings specified in the description. The novel compounds interact with tubulin by stabilising the microtubuli which are formed. They are able to influence the cell division phase-specifically and are suitable for treating malignant tumours such as cancers of the ovaries, stomach, colon, glands, breasts, lungs and head and neck, malignant melanoma and acute lymphocytic and myelocytic leukaemia. The compounds are also suitable for anti-angiogenesis therapy and for treating chronic inflammatory diseases (psoriasis, arthritis) and can be deposited on or in polymer materials in order to prevent uncontrolled cell proliferations on medical implants and to improve the compatibility thereof. The inventive compounds can be used alone or in combination with other principles and classes of substances that can be used in the therapy of tumours in order to achieve additive or synergistic effects.
PCT/EP2000/001331 1999-02-18 2000-02-18 Novel epothilone derivatives, method for producing them and their pharmaceutical use Ceased WO2000049019A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU38048/00A AU3804800A (en) 1999-02-18 2000-02-18 Novel epothilone derivatives, method for producing them and their pharmaceuticaluse

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19908760A DE19908760A1 (en) 1999-02-18 1999-02-18 New, chemically and metabolically stable epothilon derivatives having modified macrocyclic ring, useful e.g. for treating malignant tumors or chronic inflammatory disease, are cell division regulators
DE19908760.1 1999-02-18

Publications (2)

Publication Number Publication Date
WO2000049019A2 WO2000049019A2 (en) 2000-08-24
WO2000049019A3 true WO2000049019A3 (en) 2001-03-01

Family

ID=7899229

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/001331 Ceased WO2000049019A2 (en) 1999-02-18 2000-02-18 Novel epothilone derivatives, method for producing them and their pharmaceutical use

Country Status (3)

Country Link
AU (1) AU3804800A (en)
DE (1) DE19908760A1 (en)
WO (1) WO2000049019A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849651B2 (en) 1996-12-03 2005-02-01 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6965034B2 (en) 1996-12-03 2005-11-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4499359B2 (en) * 2001-02-27 2010-07-07 ノバルティス アーゲー Combination comprising a signal conversion inhibitor and an epothilone derivative
EE05417B1 (en) * 2001-03-14 2011-06-15 Bristol-Myers Squibb Company Combination therapy of epothilone analogues with chemotherapeutic agents
TWI315982B (en) * 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
AU2008203233B2 (en) * 2001-07-19 2010-04-29 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
US20030176368A1 (en) * 2001-09-06 2003-09-18 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
TWI287986B (en) * 2001-12-13 2007-10-11 Novartis Ag Use of Epothilones for the treatment of the carcinoid syndrome
ATE452896T1 (en) 2002-03-12 2010-01-15 Bristol Myers Squibb Co C3-CYANOEPOTHILONE DERIVATIVES
US20050271669A1 (en) * 2002-06-10 2005-12-08 Hohneker John A Combinations comprising epothilones and pharmaceutical uses thereof
ATE350383T1 (en) 2002-08-23 2007-01-15 Sloan Kettering Inst Cancer SYNTHESIS OF EPOTHILONES, INTERMEDIATE PRODUCTS THEREOF, ANALOGUES AND USES THEREOF
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP1674098A1 (en) 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
CA2628227A1 (en) * 2005-11-22 2007-05-31 The Scripps Research Institute Chemical synthesis of a highly potent epothilone
EP2065054A1 (en) 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Combinations comprising a prostaglandin and uses thereof
DE102007059752A1 (en) 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Functionalized solid polymer nanoparticles containing epothilones
EP2070521A1 (en) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Surface-modified nanoparticles
EP2210584A1 (en) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
US9717803B2 (en) 2011-12-23 2017-08-01 Innate Pharma Enzymatic conjugation of polypeptides
EP2872894B1 (en) 2012-07-13 2019-04-17 Innate Pharma Screening of conjugated antibodies
WO2014072482A1 (en) 2012-11-09 2014-05-15 Innate Pharma Recognition tags for tgase-mediated conjugation
WO2014140300A1 (en) 2013-03-15 2014-09-18 Innate Pharma Solid phase tgase-mediated conjugation of antibodies
US10071169B2 (en) 2013-06-20 2018-09-11 Innate Pharma Enzymatic conjugation of polypeptides
WO2014202775A1 (en) 2013-06-21 2014-12-24 Innate Pharma Enzymatic conjugation of polypeptides
WO2019092148A1 (en) 2017-11-10 2019-05-16 Innate Pharma Antibodies with functionalized glutamine residues

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997019086A1 (en) * 1995-11-17 1997-05-29 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilone derivatives, preparation and use
WO1999007692A2 (en) * 1997-08-09 1999-02-18 Schering Aktiengesellschaft New epothilone derivatives, method for producing same and their pharmaceutical use
WO1999065913A2 (en) * 1998-06-18 1999-12-23 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilone minor constituents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997019086A1 (en) * 1995-11-17 1997-05-29 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilone derivatives, preparation and use
WO1999007692A2 (en) * 1997-08-09 1999-02-18 Schering Aktiengesellschaft New epothilone derivatives, method for producing same and their pharmaceutical use
WO1999065913A2 (en) * 1998-06-18 1999-12-23 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilone minor constituents

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHOU T C ET AL: "DESOXYEPOTHILONE B: AN EFFICACIOUS MICROTUBULE-TARGETED ANTITUMOR AGENT WITH A PROMISING IN VIVO PROFILE RELATIVE TO EPOTHILONE B", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON, vol. 95, no. 16, 1998, pages 9642 - 9647, XP000910107, ISSN: 0027-8424 *
D SCHINZER ET AL: "ANGEWANDTE CHEMIE,DE,VCH VERLAGSGESELLSCHAFT, WEINHEIM", ANGEWANDTE CHEMIE,DE,VCH VERLAGSGESELLSCHAFT, WEINHEIM, vol. 109, no. 5, 1997, pages 543 - 544, XP002095720, ISSN: 0044-8249 *
HANESSIAN, STEPHEN ET AL: "Total Synthesis and Absolute Configuration of (-)-Anthoplalone", J. ORG. CHEM. (1999), 64(13), 4893-4900, XP002152894 *
K C NICOLAOU ET AL: "ANGEWANDTE CHEMIE,VCH VERLAGSGESELLSCHAFT, WEINHEIM,DE", ANGEWANDTE CHEMIE,VCH VERLAGSGESELLSCHAFT, WEINHEIM,DE, vol. 109, no. 19, 1997, pages 2181 - 2187, XP002095723, ISSN: 0044-8249 *
K C NICOLAOU ET AL: "NATURE,MACMILLAN JOURNALS LTD. LONDON,GB", NATURE,MACMILLAN JOURNALS LTD. LONDON,GB, vol. 387, no. 6630, 15 May 1997 (1997-05-15), pages 268 - 272, XP002095721, ISSN: 0028-0836 *
K C NICOLAOU ET AL: "Probing the ring size of epothilones: total synthesis of [14]-, [15]-, [17]-, and [18]Epothilones A", ANGEWANDTE CHEMIE. INTERNATIONAL EDITION,DE,VERLAG CHEMIE. WEINHEIM, vol. 37, no. 1/02, 1998, pages 81 - 84, XP002131226, ISSN: 0570-0833 *
ZHEN YANG ET AL: "ANGEWANDTE CHEMIE,DE,VCH VERLAGSGESELLSCHAFT, WEINHEIM", ANGEWANDTE CHEMIE,DE,VCH VERLAGSGESELLSCHAFT, WEINHEIM, vol. 109, no. 1/02, 1997, pages 170 - 172, XP002095722, ISSN: 0044-8249 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849651B2 (en) 1996-12-03 2005-02-01 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6965034B2 (en) 1996-12-03 2005-11-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6972335B2 (en) 1996-12-03 2005-12-06 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
USRE41990E1 (en) 1996-12-03 2010-12-07 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof

Also Published As

Publication number Publication date
DE19908760A1 (en) 2000-08-24
AU3804800A (en) 2000-09-04
WO2000049019A2 (en) 2000-08-24

Similar Documents

Publication Publication Date Title
WO2000049019A3 (en) Novel epothilone derivatives, method for producing them and their pharmaceutical use
WO1999007692A3 (en) New epothilone derivatives, method for producing same and their pharmaceutical use
WO2001081342A3 (en) Novel epothilone derivatives, method for the preparation thereof and their pharmaceutical use
PH12020551572A1 (en) Heterocyclic compounds as immunomodulators
GEP20022653B (en) Processes and Intermediates for Preparing Anti-Cancer Compounds
EG24928A (en) Heterocyclic inhibitors of mek and methods of use thereof
BG104561A (en) Aryl fused azapolycyclic compounds
AU2003291002A1 (en) Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
ATE171171T1 (en) ALPHA-AMINOKETONE DERIVATIVES
GEP20043250B (en) Use of Indolyl-3-Glyoxylic Acid Derivatives as Anti-tumor Means and Pharmaceutical Compositions Containing the Same
BR0316296A (en) Lapacone compounds and their methods of use
ATE209177T1 (en) BIPHENYL DERIVATIVES SUBSTITUTED BY AN AROMATIC OR HETEROAROMATIC RADICAL AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME
DE60209721D1 (en) OXAZOLO AND FUROPYRIMIDINES AND THEIR USE AS MEDICAMENTS AGAINST TUMORS
DE69907419D1 (en) Antitumorwirkstoffe
AU1206292A (en) Therapeutic agents for the treatment of multidrug resistance to cancers
MY133474A (en) Aryl fused azapolycyclic compounds
WO2001081341A3 (en) 9-oxa-epothilon derivatives, method for the production and use thereof in pharmaceutical preparations
AU5236393A (en) Aryl substituted heterocyclic compounds
YU46302A (en) Substituted pyrroles
IL172538A0 (en) Depsipeptide compounds, pharmaceutical compositions containing the same and processes for the preparation thereof
DE69132050D1 (en) COMPOSITIONS OF GROWTH FACTORS, PRODUCTION AND USE
ATE293983T1 (en) USE OF N-ACETYL-D-GLUCOSAMINE IN THE PRODUCTION OF A MEDICINAL PRODUCT FOR SUPPRESSING THE SIDE EFFECTS OF RADIATION THERAPY AND CHEMOTHERAPY
MY126998A (en) Substituted pyrroles.
DE02723255T1 (en) METRONOMIC DOSAGE OF TAXANE FOR INHIBITING CANCER GROWTH
MXPA06002939A (en) 6-aryl-7-halo-imidazo[1,2-a]pyrimidines as anticancer agent.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG